Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of June 2022, with the filing date recorded as June 27, 2022. The document serves primarily to notify the SEC of the cessation of securities trading under the ticker symbol "ATH."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance and regulatory notifications rather than financial performance data for this specific period.
Material Changes
- Cessation of Securities: The primary material event reported is the notification of the cessation of securities trading for the company (Exhibit 99.1).
- Registration Statements: The filing is incorporated by reference into multiple Registration Statements on Form S-8 and Form F-3.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implication of the cessation of securities. No unusual items or contingencies are detailed in the provided text.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the reason for the cessation of trading.
- Confirm the current listing status of Alterity Therapeutics Limited on relevant exchanges.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity plans.
- Check for subsequent filings that may provide financial updates, as this 6-K contains no financial data.